Using brain activity markers to predict response to accelerated iTBS for OCD
Official title: Investigation of the Relationship Between Electrophysiological Biomarkers and Treatment Response in Patients Diagnosed With Obsessive-Compulsive Disorder Undergoing Transcranial Magnetic Stimulation Therapy
Run by Istanbul University - Cerrahpasa · NCT07561528 · Data updated 2026-11-12
This will try accelerated intermittent Theta Burst Stimulation (iTBS) targeting the dmPFC and ACC to reduce symptoms in adults (18–65) with treatment‑resistant OCD and to find brain activity markers that predict who benefits.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Istanbul University - Cerrahpasa Academic / other |
| Locations | 1 site (Istanbul, Bakirkoy) |
| Status | Recruiting |
| Started | January 1, 2026 |
| Main results expected | February 1, 2027 |
| Study ends | April 1, 2027 |
| Registry record updated | May 8, 2026 |
| Trial ID | NCT07561528 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–65 with DSM‑5 OCD, Y‑BOCS ≥20, inadequate response to at least one SSRI, stable medications for two months, and no contraindications to TMS.
✕Probably not a fit
People with conditions that increase seizure risk, metal or electronic implants in the head/neck, prior neurosurgery, severe neurodegenerative disease, or those with milder OCD (Y‑BOCS <20) are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional protocol enrolls 30 adults (18–65) with DSM‑5 obsessive‑compulsive disorder who have not responded adequately to at least one SSRI. Participants receive an intensive 7‑day accelerated iTBS program with four sessions per day (28 sessions total) targeted to the dorsomedial prefrontal cortex and anterior cingulate cortex. Clinical symptoms are measured before and after treatment using standardized scales (including Y‑BOCS and Hamilton measures), while EEG microstates and heart rate variability are recorded as candidate electrophysiological biomarkers. Medication doses must be stable for at least two months and common TMS contraindications (for example, seizure risk or metal implants) exclude participation.
Why it matters
Potential benefit: If successful, this approach could produce faster symptom reduction for some people with treatment‑resistant OCD and help clinicians identify who is most likely to benefit.
How similar studies have gone: Previous TMS and iTBS studies for OCD have shown mixed but promising results, though accelerated multi‑session protocols and biomarker‑guided selection remain relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Being between 18 and 65 years of age. * Being diagnosed with Obsessive-Compulsive Disorder (OCD) according to DSM-5 criteria. * Non-responsiveness to at least one Selective Serotonin Reuptake Inhibitor (SSRI) treatment at an adequate dose and duration. * Having a Y-BOCS score of ≥20 following the initial evaluation. * No change in the current medications within the last 2 months and a commitment to maintaining stable doses throughout the study. * Providing informed consent and having no contraindications for TMS. Exclusion Criteria: * Severe neurological disorders or neurodegenerative diseases. * Any condition associated with increased seizure risk * History of cochlear implants, metal implants in the head and neck area, cardiac pacemakers, deep brain stimulation, or vagus nerve stimulation. * History of neurosurgical intervention. * General contraindications for Transcranial Magnetic Stimulation therapy.
Where it's running
-
Cerrahpaşa Tıp Fakültesi Prof. Dr. Murat Dilmener Hastanesi
Istanbul, Bakirkoy, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: Sarp Yoldas, MD
- Email: sarpyoldas@gmail.com
- Phone: +905069898506
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low-intensity focused ultrasound targeting the subthalamic nucleus for OCD
A short test is being done to see if a wearable, non-invasive ultrasound device can safely and tolerably help adults with OCD by targeting a brain region called the subthalamic nucleus.
-
Mindfulness-Based Cognitive Therapy for OCD Delivered Online
This study tests a synchronous online MBCT program for adults with OCD to see if it is acceptable and feasible and to explore links between biological markers, OCD severity, and treatment response.
-
Targeted brain stimulation for OCD: test of tTIS on nucleus accumbens
This study tests whether targeted temporal interference stimulation of the nucleus accumbens can help reduce obsessive-compulsive symptoms in adults with OCD, compared with sham stimulation.
-
Anxiety Skills Study: See if video skill training plus therapy helps people with anxiety
This study tests whether a brief video-based skill training can help people with anxiety as well as four therapy sessions, and how durable the effects are over a year.
-
AttunE LIFU for OCD: a non-invasive brain stimulation study
This trial tests ATTN201, a wearable ultrasound headband, to see if it helps adults with OCD compared to a sham treatment.
-
Combined ERP and Habit Reversal Therapy for Tourettic OCD
This study tests whether a merged Exposure and Response Prevention and Habit Reversal Therapy helps adults with Tourettic OCD more than either therapy alone or basic psychoeducation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.